鲁晓伍;张爱华;

• 1:武汉生物制品研究所免疫学研究室

摘要(Abstract)：

治疗性疫苗不仅具有预防性疫苗的间接靶向特异性和长效性等特点,而且还具有治疗性药物的疗效,尤其对一些目前尚无特效治疗药物的传染性疾病及肿瘤等可以起到治疗作用。近年来,治疗性疫苗的研究已取得了全面的进展。本文就治疗性疫苗的意义、作用机理及研究进展作一综述。

关键词(KeyWords)： 治疗性疫苗;免疫治疗;慢性感染性疾病;肿瘤

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 鲁晓伍;张爱华;

DOI: 10.13200/j.cjb.2011.04.119.luxw.012

参考文献(References)：

• [1]Sallberg M,Weiland M,Frelin L.Therapeutic vaccines:chal-lenges of chronic viral infections[J].Drug Discovery Today:Ther-apeutic Strategies,2007,4(4):253-266.
• [2]Lage A.Therapeutic vaccines:changing the dominant paradigm inadvanced cancer[J].Vacci Monitor,2009,18(Suppl):1.
• [3]González G,Crombet T,Neninger E,et al.Therapeutic vaccina-tion with epidermal growth factor(EGF)in advanced lung canceranalysis of pooled data from three clinical trials[J].Human Vac-cin,2007,3(1):8-13.
• [4]我国治疗性乙肝疫苗研究获重大进展[J].中国生物工程杂志,2006,26(11):97-99.
• [5]Farray D,Clark JI.Vaccine therapy of malignant melanoma[J].Clin Appl Immunol Rev,2006,6(3):217-230.
• [6]Tartaglia J,Bonnet MC,Berinstein N,et al.Therapeutic vaccinesagainst melanoma and colorectal cancer[J].Vaccine,2001,19(17-19):2571-2575.
• [7]Betting DJ,Mu XY,Kafi K,et al.Enhanced immune stimulationby a therapeutic lymphoma tumor antigen vaccine produced in in-sect cells involves mannose receptor targeting to antigen presentingcells[J].Vaccine,2009,27(2):250-259.
• [8]Kiessling A,Fussel S,Wehner R,et al.Advances in specific im-munotherapy for prostate cancer[J].Eur Urol,2008,53(4):694-708.
• [9]Curigliano G,Rescigno M,Goldhirsch A.Immunology and breastcancer:therapeutic cancer vaccines[J].Breast,2007,16(Suppl 2):S20-S26.
• [10]Gaudernack G.Prospects for vaccine therapy for pancreatic can-cer[J].Best Pract Res Clin Gastroenterol,2006,20(2):299-314.
• [11]Van Doorslaer K,Reimers LL,Studentsor YY,et al.Serologicalresponse to an HPV16 E7 based therapeutic vaccine in womenwith high-grade cervical dysplasia[J].Gynecol Oncol,2010,116(2):208-212.
• [12]Reinis M.BiovaxID,a personalized therapeutic vaccine againstB-cell lymphomas[J].Curr Opin Mol Ther,2008,10(5):526-534.
• [13]Liu B,Ye D,Song X,et al.A novel therapeutic fusion proteinvaccine by two different families of heat shock proteins linkedwith HPV16 E7 generates potent antitumor immunity and antian-giogenesis[J].Vaccine,2008,26(10):1387-1396.
• [14]Venuti A,Massa S,Mett V,et al.An E7-based therapeuticvaccine protects mice against HPV16 associated cancer[J].Vac-cine,2009,27(25-26):3395-3397.
• [15]Chuang CM,Hoory T,Monie A,et al.Enhancing therapeuticHPV DNA vaccine potency through depletion of CD4+CD25+Tregulatory cells[J].Vaccine,2009,27(5):684-689.
• [16]Kim D,Gambhira R,Karanam B,et al.Generation and charac-terization of a preventive and therapeutic HPV DNA vaccine[J].Vaccine,2008,26(3):351-360.中国生物制品学杂志2011年4月第24卷第4期Chin J Biologicals April 2011,Vol.24 No.4
• [17]Einstein MH,Kadish AS,Burk RD,et al.Heat shock fusionprotein-based immunotherapy for treatment of cervical intraep-ithelial neoplasia III[J].Gynecol Oncol,2007,106(3):453-460.
• [18]Clinical trails.gov.Safety study to test the safety of HspE7 andPoly-ICLC given in patients with cervical intraepithelial neopla-sia//http://www.clinicaltrials.gov/ct/show/NCT00493545or-der=11.
• [19]Lu D,Hoory T,Monie A,et al.Treatment with demethylatingagent,5-aza-2′-deoxycytidine enhances therapeutic HPV DNAvaccine potency[J].Vaccine,2009,27(32):4363-4369.
• [20]Ramírez BS,Alpízar YA,Ferníndez DR,et al.Anti-EGFR acti-vation,anti-proliferative and pro-apoptotic effects of polyclonalantibodies induced by EGFR-based cancer vaccine[J].Vaccine,2008,26(38):4918-4926.
• [21]Andersen MH,Srensen RB,Schrama D,et al.Cancer treat-ment:the combination of vaccination with other therapies[J].Cancer Immunol Immunother,2008,57(11):1735-1743.
• [22]Mori F,Giannetti P,Peruzzi D,et al.A therapeutic cancer vac-cine targeting carcinoembryonic antigen in intestinal carcinomas[J].Hum Gene Ther,2009,20(2):125-136.
• [23]Tseng CW,Monie A,Trimble C,et al.Combination of treatmentwith death receptor 5-specific antibody with therapeutic HPVDNA vaccination generates enhanced therapeutic anti-tumor ef-fects[J].Vaccine,2008,26(34):4314-4319.
• [24]Bianco C,Salomon DS.Human Cripto-1 as a target for a cancervaccine:WO2008040759[J].Expert Opin Ther Pat,2009,19(2):141-144.
• [25]Li QX,Liu G,Wong-Staal F.Oncolytic virotherapy as a person-alized cancer vaccine[J].Int J Cancer,2008,123(3):493-499.
• [26]刘朝霞,田泽维.治疗性乙肝疫苗研究进展[J].第一军医大学分校学报,2004,27(2):195-199.
• [27]Wedemeyer H,Schuller E,Schlaphoff V,et al.Therapeutic vac-cine IC41 as late add-on to standard treatment in patients withchronic hepatitis C[J].Vaccine,2009,27(37):5142-5151.
• [28]Gandhi RT,O’Neill D,Bosch RJ,et al.A randomized thera-peutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs.canarypox-HIV alone in HIV-1-infected patients on antiretroviraltherapy[J].Vaccine,2009,27(43):6088-6094.
• [29]Pappas J,Messinese N.Efficient priming of human Cd4 T-cellsin vitro by the antigenic peptide component of a herpes therapeu-tic vaccine[J].J Clin,2006,4:486.
• [30]Wang B,Zhang WJ,Du XG.I-63 development of therapeuticvaccine against HBV by the use of adjuvant to boost the cell-me-diated immunity[J].Int J Infect Dis,2008,12(3):522-523.
• [31]Shi TD,Wu YZ,Jia ZC,et al.Therapeutic polypeptides based onHBcAg(18-27)CTL epitope can induce antigen-specific CD(8)(+)CTL-mediated cytotoxicity in HLA-A2 transgenic mice[J].World J Gastroenterol,2004,10(8):1222-1226.
• [32]Xu W,Chu Y,Zhang R,et al.Endoplasmic reticulum targetingsequence enhances HBV-specific cytotoxic T lymphocytes in-duced by a CTL epitope-based DNA vaccine[J].Virology,2005,334(2):255-263.
• [33]Habersetzer F,Zarski JP,Leroy V,et al.A novel vectorizedHCV therapeutic vaccine(Tg4040):results of a phase 1 study innaive patients chronically infected by HCV[C].EASL,2009.
• [34]我国丙型肝炎治疗性疫苗研究获得重大突破[J].中国药房,2003,14(4):227.
• [35]Longo O,Tripiciano A,Fiorelli V,et al.Phase I therapeutic tri-al of the HIV-1 Tat protein and long term follow-up[J].Vac-cine,2009,27(25-26):3306-3312.
• [36]Kran AM,Sommerfelt MA,Srensen B,et al.Reduced viralburden amongst high responder patients following HIV-1 p24peptide-based therapeutic immunization[J].Vaccine,2005(31),23:4011-4015.
• [37]Nyhus J,Kran AM,Sommerfelt MA,et al.Multiple antigen con-centrations in delayed-type hypersensitivity(DTH)and responsediversity during and after immunization with a peptide-basedHIV-1 immunotherapy candidate(Vacc-4x)[J].Vaccine,2006,24(10):1543-1550.
• [38]Pett SL.Immunotherapies in HIV-1 infection[J].Curr Opin HIVAIDS,2009,4(3):188-193.